Baker Bros. Advisors IPSC Position
Exited5-Fund ConvergenceBaker Bros. Advisors exited their position in Century Therapeutics, Inc. (IPSC) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
IPSC is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Full company profile →Short Interest
5.6%
7.9 days to cover
Baker Bros. Advisors IPSC Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -241,684 | $0 |
| Q1 2025 | Decreased | 241,684 | -555,776 | $115K |
| Q4 2024 | Held | 797,460 | — | $805K |
| Q3 2024 | Held | 797,460 | — | $1.4M |
| Q2 2024 | Held | 797,460 | — | $2.0M |
| Q1 2024 | Held | 797,460 | — | $3.3M |
| Q4 2023 | Decreased | 797,460 | -351,880 | $2.6M |
| Q3 2023 | Held | 1,149,340 | — | $2.3M |
| Q2 2023 | Held | 1,149,340 | — | $3.6M |
| Q1 2023 | New | 1,149,340 | +1,149,340 | $4.0M |
Frequently Asked Questions
Does Baker Bros. Advisors own IPSC?
No. Baker Bros. Advisors exited their position in Century Therapeutics, Inc. (IPSC) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own IPSC?
5 specialist biotech hedge funds currently hold IPSC, including Driehaus Capital, Casdin Capital, Boxer Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy IPSC?
Baker Bros. Advisors's position in IPSC was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's IPSC position increasing or decreasing?
Baker Bros. Advisors completely exited their IPSC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IPSCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →